Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaji Kumar

Showing results (191-200 of 515) with videos related to

Pageof 52
Sort By:
Blood Cancer Journal|June 11, 2024
Performance of newer myeloma staging systems in a contemporary, large patient cohortGhulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kumar, et al.
British Journal of Haematology|December 5, 2009
Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myelomaShirshendu Sinha, S Vincent Rajkumar, Martha Q Lacy, et al.
Blood Cancer Journal|March 20, 2021
Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myelomaKalyan Nadiminti, M Hasib Sidiqi, Kapil Meleveedu, et al.
Blood Cancer Journal|April 23, 2022
Financial toxicity in hematological malignancies: a systematic reviewEvguenia Ouchveridze, Rahul Banerjee, Aakash Desai, et al.
American Journal of Hematology|May 15, 2024
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myelomaShaji Kumar, S Vincent Rajkumar, Dragan Jevremovic, et al.
Bone Marrow Transplantation|October 6, 2022
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myelomaCharalampos Charalampous, Utkarsh Goel, Morie Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significanceShaji Kumar, S Vincent Rajkumar, Robert A Kyle, et al.
BMC Cancer|April 29, 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myelomaMeletios Dimopoulos, Pieter Sonneveld, Salomon Manier, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 11, 2015
Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo ClinicMuhammad A Mir, Prashant Kapoor, Shaji Kumar, et al.
Mayo Clinic Proceedings|March 5, 2008
Serum uric acid: novel prognostic factor in primary systemic amyloidosisShaji Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Pageof 52

Showing results (191-200 of 515) with videos related to

Sort By:
Pageof 52
Blood Cancer Journal|June 11, 2024
Performance of newer myeloma staging systems in a contemporary, large patient cohortGhulam Rehman Mohyuddin, Samuel M Rubinstein, Shaji Kumar, et al.
British Journal of Haematology|December 5, 2009
Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myelomaShirshendu Sinha, S Vincent Rajkumar, Martha Q Lacy, et al.
Blood Cancer Journal|March 20, 2021
Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myelomaKalyan Nadiminti, M Hasib Sidiqi, Kapil Meleveedu, et al.
Blood Cancer Journal|April 23, 2022
Financial toxicity in hematological malignancies: a systematic reviewEvguenia Ouchveridze, Rahul Banerjee, Aakash Desai, et al.
American Journal of Hematology|May 15, 2024
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myelomaShaji Kumar, S Vincent Rajkumar, Dragan Jevremovic, et al.
Bone Marrow Transplantation|October 6, 2022
Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myelomaCharalampos Charalampous, Utkarsh Goel, Morie Gertz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2005
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significanceShaji Kumar, S Vincent Rajkumar, Robert A Kyle, et al.
BMC Cancer|April 29, 2024
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myelomaMeletios Dimopoulos, Pieter Sonneveld, Salomon Manier, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 11, 2015
Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo ClinicMuhammad A Mir, Prashant Kapoor, Shaji Kumar, et al.
Mayo Clinic Proceedings|March 5, 2008
Serum uric acid: novel prognostic factor in primary systemic amyloidosisShaji Kumar, Angela Dispenzieri, Martha Q Lacy, et al.
Pageof 52